Use of inhibitors of brutons tyrosine kinase (btk)
AssigneePharmacyclics, Inc.
InventorsJoseph J. Buggy, Gwen Fyfe, Laurence Elias, David J. Loury
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Claims21
(canceled)
A method for treating follicular lymphoma (FL) in an individual comprising administering to the individual a dose of 560 mg of an inhibitor of Bruton's tyrosine kinase (Btk), wherein the inhibitor of Btk has the structure:
Dependencies are inferred from the claim text.